News Center

Mexico stocks lower at close of trade; S&P/BMV IPC down 0.68%

Mexico stocks lower at close of trade; S&P/BMV IPC down 0.68%

Investing.com – Mexico stocks were lower after the close on Friday, as losses in the Industrials, Consumer Goods & Services and Consumer Staples sectors led shares lower.At the close in Mexico, the S&P/BMV IPC fell 0.68% to hit a new 1-month low.The best performers of the session on the S&P/BMV IPC were Industrias Penoles Sab De CV (BMV:PEOLES), which rose 3.28% or 16.84 points to ...

2025-06-15 04:12:29
23andMe’s founder Anne Wojcicki wins bid for bankrupt DNA testing firm

23andMe’s founder Anne Wojcicki wins bid for bankrupt DNA testing firm

By Siddhi Mahatole and Mariam Sunny (Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron (NASDAQ:REGN) Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction. Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research I ...

2025-06-15 04:11:38
Exclusive-Google, Scale AI’s largest customer, plans split after Meta deal, sources say

Exclusive-Google, Scale AI’s largest customer, plans split after Meta deal, sources say

By Anna Tong, Kenrick Cai and Krystal Hu SAN FRANCISCO (Reuters) -Alphabet’s Google (NASDAQ:GOOGL), the largest customer of Scale AI, plans to cut ties with Scale after news broke that rival Meta (NASDAQ:META) is taking a 49% stake in the AI data-labeling startup, five sources familiar with the matter told Reuters. Google had planned to pay Scale AI about $200 million this year for the human-l ...

2025-06-15 04:10:51
US FDA extends review of KalVista’s swelling disorder drug due to heavy workload

US FDA extends review of KalVista’s swelling disorder drug due to heavy workload

By Puyaan Singh (Reuters) -KalVista Pharmaceuticals’ said on Friday that the U.S. Food and Drug Administration had extended the review of its drug for a type of hereditary swelling disorder due to heavy workload and limited resources. The FDA indicated that it now expects to deliver a decision within four weeks, KalVista said. The original target action date for the decision on the medication, ...

2025-06-15 04:10:01